•  
  •  
 

Abstract

Ropinirole HCl is a non-ergoline dopamine agonist which is recommended for the treatment of both Parkinson’s disease and Restless Legs Syndrome (RLS). Its half-life is about 6 hours and it is metabolized in the liver primarily by CYP1A2. Its metabolites are water-soluble and rapidly excreted from the body in urine. However, its oral bioavailability is low. Therefore, this current project aimed to produce and evaluate sustained release ropinirole microparticles coated with Eudragit® RS 100 and RL 100 by varying polymer types and concentrations. Ropinirole microparticles were prepared by oil in oil emulsion solvent evaporation technique. Emulsifier concentration was constantly set at 2% with a stirring speed of 500 pm. FTIR analysis of microparticles, drugs, and polymers was carried out. Analysis of compatibility, particle size, encapsulation effciency, yield, flow properties, and release profile were also performed. The optical microscope showed the spherical microparticles with better flow properties and encapsulation. Ropinirole FTIR analysis produced sharp characteristic bands of C=O stretching at 1699 cm-1, bending of CH3 at 1457 cm-1, C=C aromatic stretching at 1521 cm-1 and 1541 cm-1, and C-H aromatic bending at 765 cm-1. Eudragit® RS 100 and Eudragit® RL 100 showed a major peak with C=O stretching at 1716 cm-1. Within 8 hours, the drug release was in the range of 47.48-98.78%. Increasing the polymer concentration increased particle size, entrapment efficiency, and sustained drug release. Eudragit® RS 100 alone achieved a better sustained release than in combination with Eudragit® RL 100 or Eudragit® RL 100 alone.

References

Avachat, A., Bornare, P., & Dash, R. (2011). Sustained release microspheres of ropinirole hydrochloride: effect of process parameters. Acta Pharmaceutica, 61(4), 363-376.

Azeem, A., Talegaonkar, S., Negi, L. M., Ahmad, F. J., Khar, R. K., & Iqbal, Z. (2012). An oil-based nanocarrier system for transdermal delivery of ropinirole is a mechanistic, pharmacokinetic, and biochemical investigation. International Journal of Pharmaceutics, 422(1), 436-444.

Bhardwaj, P., Chaurasia, H., Chaurasia, D., Prajapati, S. K., & Singh, S. (2010). Formulation and in-vitro evaluation of floating micro balloons of indomethacin. Acta Poloniae Pharmaceutica, 67(3), 291-298.

Biswal, I., Dinda, A., Das, D., Si, S., & Chowdary, K. (2011). Encapsulation protocol for highly hydrophilic drug using non-biodegradable polymer. International Journal of Pharmacy and Pharmaceutical Sciences, 3(2), 256–259.

Costa, P., & Sousa Lobo, J. M. (2016). Modeling and comparison of dissolution profiles: A review. Drug Development and Industrial Pharmacy, 42(5), 729-738

De Caro, V., Giandalia, G., Siragusa, M., Sutera, F., & Giannola, L. (2012). A new perspective in treating Parkinson’s disease: Studies on permeation of ropinirole through the buccal mucosa. International Journal of Pharmaceutics, 429(1), 78-83.

Evonik. (2015). Eudragit® RL 100, Eudragit® RL PO, Eudragit® RS 100 and Eudragit® RS PO. Evonik Nutrition & Care GmbH.

Ferreira, I. S., Bettencourt, A., Bétrisey, B., Gonçalves, L. M., Trampuz, A., & Almeida, A. J. (2015). Improvement of the antibacterial activity of daptomycin-loaded polymeric microparticles by Eudragit RL 100: An assessment by isothermal microcalorimetry. International Journal of Pharmaceutics, 485(1), 171-182.

Freeman, K. B., Heal, D. J., McCreary, A. C., & Woolverton, W. L. (2012). Assessment of ropinirole as a reinforcer in rhesus monkeys. Drug and Alcohol Dependence, 125(1), 173–177.

Garud, N., & Garud, A. (2012). Preparation and in-vitro evaluation of metformin microspheres using non-aqueous solvent evaporation technique. Tropical Journal of Pharmaceutical Research, 11(4), 577-583.

Guo, K., & Chu, C. (2009). Biodegradable and injectable paclitaxel‐loaded poly (ester amide) s microspheres: Fabrication and characterization. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 89(2), 491-500.

Hou, C.-D., Wang, J.-X., Le, Y., Zou, H.-K., & Zhao, H. (2012). Preparation of azithromycin nanosuspensions by reactive precipitation method. Drug Development and Industrial Pharmacy, 38(7), 848–854.

Jelvehgari, M., Barar, J., Valizadeh, H., Shadrou, S., & Nokhodchi, A. (2011). Formulation, characterization, and in vitro evaluation of theophylline-loaded Eudragit RS 100 microspheres prepared by an emulsion-solvent diffusion/evaporation technique. Pharmaceutical Development and Technology, 16(6), 637–644.

Joshi, A. S., Patil, C. C., Shiralashetti, S. S., & Kalyane, N. V. (2013). Design, characterization, and evaluation of Eudragit microspheres containing glipizide. Drug Invention Today, 5(3), 229–234.

Khan, M. I., Madni, A., Ahmad, S., Khan, A., Rehmanand, M., & Mahmood, M. A. (2015). ATR-FTIR based pre and post formulation compatibility studies for the design of niosomal drug delivery system containing nonionic amphiphiles and chondroprotective drug. Journal of the Chemical Society of Pakistan, 37(3).

Khan, S., Patil, K., Bobade, N., Yeole, P., & Gaikwad, R. (2010). Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. Journal of Drug Targeting, 18(3), 223-234.

Kim, K.-S., & Park, S.-J. (2010). Characterization and release behaviours of porous PCL/Eudragit RS microcapsules containing tulobuterol. Colloids and Surfaces B: Biointerfaces, 76(2), 404-409.

Kumar, B. P., Chandiran, I. S., Bhavya, B., & Sindhuri, M. (2011). Microparticulate drug delivery system: a review. Indian Journal of Pharmaceutical Science & Research, 1(1), 19–37.

Liu, L. X., Marziano, I., Bentham, A., Litster, J. D., White, E., & Howes, T. (2008). Effect of particle properties on the flowability of ibuprofen powders. International Journal of Pharmaceutics, 362(1), 109-117.

Mao, S., Shi, Y., Li, L., Xu, J., Schaper, A., & Kissel, T. (2008). Effects of process and formulation parameters on characteristics and internal morphology of poly (d, l-lactide-co-glycolide) microspheres formed by the solvent evaporation method. European Journal of Pharmaceutics and Biopharmaceutics, 68(2), 214–223.

Martinelli, A., Bakry, A., D’Ilario, L., Francolini, I., Piozzi, A., & Taresco, V. (2014). Release behaviour and antibiofilm activity of usnic acid-loaded carboxylated poly (l-lactide) microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 88(2), 415-423.

Nath, B., Nath, L. K., & Kumar, P. (2011). Preparation and in vitro dissolution profile of zidovudine-loaded microspheres made of Eudragit RS 100, RL 100, and their combinations. Acta Poloniae Pharmaceutica, 68(3), 409–415.

Nicholson, G., Pereira, A., & Hall, G. (2002). Parkinson’s disease and anaesthesia. British Journal of Anaesthesia, 89(6), 904-916.

Nikam, A., Sahoo, P. R., Musale, S., Pagar, R. R., Paiva-Santos, A. C., & Giram, P. S. (2023). A systematic overview of eudragit® based copolymer for smart healthcare. Pharmaceutics, 15(2), 587. https://doi.org/10.3390/pharmaceutics15020587.

Pringsheim, T., Jette, N., & Frolkis, A. (2014). The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Movement Disorders, 29(13), 1583-1590.

Qi, F., Wu, J., Yang, T., Ma, G., & Su, Z. (2014). Mechanistic studies for monodisperse exenatide-loaded PLGA microspheres prepared by different methods based on SPG membrane emulsification. Acta Biomaterials, 10(10), 4247-4256.

Quilici, S., Abrams, K., Nicolas, A., Martin, M., Petit, C., LLeu, P.-L., & Finnern, H. (2008). Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in treating restless legs syndrome. Sleep Medicine, 9(7), 715–726.

Rao, N. R., & Patel, K. (2013). Formulation and evaluation of ropinirole buccal patches using different mucoadhesive polymers. RGUHS Journal of Pharmaceutical Sciences, 3(1), 32.

Rewane, A., & Nagalli, S. (2022, May 15). Ropinirole. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK554532/.

Sahoo, S. K., Mallick, A. A., Barik, B., & Senapati, P. C. (2005). Formulation and in vitro evaluation of eudragit® microspheres of stavudine. Tropical Journal of Pharmaceutical Research, 4(1), 369-375.

Salawu, F., Olokoba, A., & Danburam, A. (2010). Current management of Parkinson’s disease. Annals of African Medicine, 9(2).

Salunkhe, S. D., Sathe, B. S., Jain, P., & Patil, R. N. (2017). Formulation and evaluation of fast dissolving oral thin film of ropinirole HCl. International Journal of Science and Research (IJSR), 6:11, 1616-1625.

Sanka, K., Poienti, S., Mohd, A. B., & Diwan, P. V. (2014). Improved oral delivery of clonazepam through liquisolid powder compact formulations: In-vitro and ex-vivo characterization. Powder Technology, 256, 336-344.

Tompson, D. J., & Vearer, D. (2007). Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s disease. Clinical Therapeutics, 29(12), 2654–2666.

Trapani, A., Laquintana, V., Denora, N., Lopedota, A., Cutrignelli, A., Franco, M., . . . Liso, G. (2007). Eudragit RS 100 microparticles containing 2-hydroxypropyl-β-cyclodextrin and glutathione: Physicochemical characterization, drug release, and transport studies. European Journal of Pharmaceutical Sciences, 30(1), 64-74.

Trivedi, P., Verma, A., & Garud, N. (2008). Preparation and characterization of aceclofenac microspheres. Asian Journal of Pharmaceutics, 2(2), 110.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.